Are all licensed haemostatic agents for haemophilia therapy accessible to patients?

Basit Öğe Kaydı
dc.authorscopusid7103356535
dc.authorscopusid6603389575
dc.authorscopusid7006410083
dc.authorscopusid56962789300
dc.authorscopusid36038519800
dc.authorscopusid35885183600
dc.authorscopusid7102428885
dc.contributor.authorBerger, Karin
dc.contributor.authorBatorova, Angelika
dc.contributor.authorBohn, Rhonda
dc.contributor.authordi Minno, Matteo
dc.contributor.authorMannucci, Pier Mannuccio
dc.contributor.authorKavakli, Kaan
dc.contributor.authorSchramm, Wolfgang
dc.date.accessioned2023-01-12T20:01:55Z
dc.date.available2023-01-12T20:01:55Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstract[No Abstract Available]en_US
dc.description.sponsorshipHospital for Sick Children (SickKids) Foundation from Bayer; Novo Nordisk Health Care AG; Pfizer; Sanofi; Takeda; Spark Therapeuticsen_US
dc.description.sponsorshipThe authors of this letter to the editor are members of the Access Expert Working Group of the International Prophylaxis Study Group (the IPSG). The opinions stated in this letter to the editor are those of the named authors and as well reflect input from the members of the IPSG Executive (Drs. Victor Blanchette, Louis Aledort and Rolf Ljung). The International Prophylaxis Study Group (IPSG), is a not-for-profit organisation funded by educational grants to the Hospital for Sick Children (SickKids) Foundation from Bayer, Novo Nordisk Health Care AG, Pfizer, Sanofi, Takeda and Spark Therapeutics. None of the industry sponsors of the IPSG, nor a commercial medical writing service were involved with the preparation of this letter to the editor.en_US
dc.identifier.doi10.1111/hae.14660
dc.identifier.endpageE258en_US
dc.identifier.issn1351-8216
dc.identifier.issn1365-2516
dc.identifier.issue6en_US
dc.identifier.pmid36122901en_US
dc.identifier.scopus2-s2.0-85138226970en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpageE256en_US
dc.identifier.urihttps://doi.org/10.1111/hae.14660
dc.identifier.urihttps://hdl.handle.net/11454/77531
dc.identifier.volume28en_US
dc.identifier.wosWOS:000859279400001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofHaemophiliaen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleAre all licensed haemostatic agents for haemophilia therapy accessible to patients?en_US
dc.typeLetteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu